



FOR IMMEDIATE RELEASE

Contact:

David Ball, Ball Consulting Group, LLC

Phone: 617-548-7809 Email: david@ballcg.com

Statement from Lee H. Rosebush, Chairman of OFA

FORT WORTH, Texas (Oct. 11, 2024) – The [Outsourcing Facilities Association, \(OFA\)](#) is greatly relieved, for our members and the many patients that they serve, that the FDA has agreed to reconsider its decision removing Tirzepatide from its drug shortage list and to allow member 503B outsourcing facilities to produce an “essential copy” version of the drug while it reconsiders. We believe that this is a fair resolution in light of the agency’s rash decision to take the drug off of the list at a time when the agency has acknowledged “supply disruptions,” which immediately created a major access issue for patients everywhere. Most important, should the FDA repeat its removal decision when a shortage still genuinely exists, we will return to court.

About Outsourcing Facilities Association

The Outsourcing Facilities Association (OFA) is the trade association representing FDA-registered 503B outsourcing facilities, which focus on providing hospitals, physicians and patients with critically needed compounded medications. OFA works with industry, government and health care providers to advocate for outsourcing facilities and their products. For more information, visit www.503Bs.org.

###